Different Platelet Activities Between Intracoronary and Peripheral Blood in Coronary Artery Disease Patients
试验速览
- 阶段
- 1 期
- 入组人数
- 90
- 试验地点
- 1
- 主要终点
- platelet aggregation
研究概览
简要总结
Antiplatelet treatment is important for coronary artery disease(CAD) patients .Some patients are resistant to antiplatelet treatment based on platelet function tests(PFT).Currently the results of PFT are mainly based on the analysis of peripheral blood. instead, adverse cardiovascular events in CAD patients may be more directly related to platelet activities in the coronary arteries. There's no evidence of system study to prove the PFT of peripheral blood can represent the platelet functions in coronary arteries.The purpose of this study is to determine the different platelet activities in the blood of peripheral vein (PV), peripheral artery (PA), intracoronary artery (IC) in the CAD patients without or with different interventions.
our study is divided into three parts: Part A: To study the different platelet activities in the blood of PV, PA, IC in the CAD patients with dual antiplatelet therapy.
Part B: To explore the different platelet activities of the above three sites in ST-segment elevation myocardial infarction (STEMI) patients who are administrated platelet membrane glycoprotein Ⅱb/Ⅲa (GPⅡb/Ⅲa) receptor antagonist ( tirofiban ) in PV or IC and dual antiplatelet therapy.
Part C: To explore the different platelet activities of the above three sites in STEMI patients who are administrated antiplatelet thrombolysin or placebo in PV and dual antiplatelet therapy.
详细描述
Part A:A total of 30 CAD patients are recruited.All patients are on loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days and a loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days. All patients plan to receive coronary arteriography (CAG) or percutaneous coronary intervention (PCI).The investigators sample blood from PV,PA and IC before PCI.Regional differences will be compared between blood samples from PV,PA and IC by light aggregometry (agonists: arachidonic acid, LTA-AA; adenosine diphosphat, LTA-ADP), VerifyNow P2Y12 assays. Differences between LTA and VerifyNow P2Y12-assay will also be compared.
Part B:A total of 30 STEMI patients are recruited.Patients are randomly assigned to 2 groups.A group(n=15) is given tirofiban through PV, the other group(n=15) is given through IC.All patients are on loading dose of 600 mg clopidogrel and 300 mg aspirin.All patients plan to receive emergency PCI. Group PV: a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.Group IC: a loading dose of 10ug/kg tirofiban is given through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h. Blood samples are collceted from PV, PA and IC before the injection of loading dose tirofiban , and 15min after the injection.Regional differences will be compared between blood samples from PV,PA and IC by LTA-AA; LTA-ADP, LTA-RIS(agonists:ristocetin),VerifyNow P2Y12 assays.
Part C:A total of 30 STEMI patients are recruited.Patients are randomly assigned to 2 groups.A group(n=15) is given antiplatelet thrombolysin(the frist antiplatelet drugs based on GP Ib receptor which completed the preclinical and phase I clinical studies,and already has entered phase II clinical studies) through PV, the other group(n=15) is given placebo through PV.All patients are on loading dose of 600 mg clopidogrel and 300 mg aspirin.All patients plan to receive emergency PCI.Both Groups are given in the same way , a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h. Blood samples are collceted from PV, PA and IC before the injection of loading dose of antiplatelet thrombolysin or placebo, and 15 min after the injection.Regional differences will be compared between blood samples from PV,PA and IC by LTA-AA; LTA-ADP, LTA-RIS and VerifyNow P2Y12 assays.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •CAD patients plan to receive coronary arteriography (CAG) or percutaneous coronary intervention (PCI).
- •Patient aged >18 years and ≦75 years old;
- •Signed inform consent
排除标准
- •Allergy or intolerance to ASA, clopidogrel , tirofiban ,antiplatelet thrombolysin;
- •Subjects at a high risk of bleeding (e.g. platelet count< 100*109/L, known bleeding diathesis , active peptic ulcer );
- •Patients who are planning to take warfarin or drugs that potentially could interfere with the anti-platelet effects .
- •severe hemodynamic instability
- •severe liver and renal dysfunction
研究组 & 干预措施
dual antiplatelet therapy
clopidogrel +aspirin
干预措施: Clopidogrel (Drug)
dual antiplatelet therapy
clopidogrel +aspirin
干预措施: Aspirin (Drug)
tirofiban in PV
clopidogrel +aspirin + tirofiban in PV
干预措施: tirofiban in PV (Drug)
tirofiban in PV
clopidogrel +aspirin + tirofiban in PV
干预措施: Aspirin (Drug)
tirofiban in PV
clopidogrel +aspirin + tirofiban in PV
干预措施: Clopidogrel (Drug)
tirofiban in IC
clopidogrel +aspirin +tirofiban in IC
干预措施: tirofiban in IC (Drug)
tirofiban in IC
clopidogrel +aspirin +tirofiban in IC
干预措施: Aspirin (Drug)
tirofiban in IC
clopidogrel +aspirin +tirofiban in IC
干预措施: Clopidogrel (Drug)
antiplatelet thrombolysin
clopidogrel +aspirin +antiplatelet thrombolysin
干预措施: antiplatelet thrombolysin (Drug)
antiplatelet thrombolysin
clopidogrel +aspirin +antiplatelet thrombolysin
干预措施: Aspirin (Drug)
antiplatelet thrombolysin
clopidogrel +aspirin +antiplatelet thrombolysin
干预措施: Clopidogrel (Drug)
placebo
clopidogrel +aspirin +placebo
干预措施: placebo (Drug)
placebo
clopidogrel +aspirin +placebo
干预措施: Aspirin (Drug)
placebo
clopidogrel +aspirin +placebo
干预措施: Clopidogrel (Drug)
结局指标
主要结局
platelet aggregation
时间窗: 2 hours
Regional differences between blood samples from PV,PA and IC by LTA and VerifyNow P2Y12 assays.The results of LTA are reported in platelet aggregation rate（%）.Platelet aggregation was induced using 0.5 mg/ml arachidonic acid (AA) and 5 μmol/l ADP.The maximum aggregation achieved during an 8-minute period was used for analysis.The results of the VerifyNow P2Y12-assay are reported in P2Y12 reaction units (PRU).(using 20 μmol/l ADP as the agonist and 22 nmol/l prostag- landin E1 (PGE1). a value that uses iso- thrombin receptor-activating peptide to approximate a baseline off-drug platelet reactivity value, and percentage inhibition.
次要结局
未报告次要终点
研究者
Chunjian Li
Professor
The First Affiliated Hospital with Nanjing Medical University